论文部分内容阅读
ALK~+弥漫大B细胞淋巴瘤(anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma,ALK~+DLBCL)是淋巴瘤中一种罕见的和具有明显差异性的病理类型,2008年WHO将其归类为DLBCL一个独特的亚型,该病侵袭性高,容易复发,目前尚无规范有效的治疗方案。采取多学科协作体系(multidisciplinary treatment,MDT)有利于制定规范化、个体化的治疗方案,探索针对ALK~+DLBCL患者更有效的治疗方法,从而让更多的患者获益。本研究分享1例2012年1月天津医科大学肿瘤医院收治的ALK~+DLBCL高剂量化疗联合自体造血干细胞移植(autologous hematopoietic stem cell transplantation,AHSCT)后复发,采用ALK激酶抑制剂克唑替尼(Crizotinib)治疗成功的案例。
ALK ~ + diffuse large B-cell lymphoma (ALK ~ + DLBCL) is a rare and significantly different pathological type in lymphoma Class for DLBCL a unique subtype, the disease is highly invasive, easy to relapse, there is no standardized and effective treatment options. Multidisciplinary treatment (MDT) facilitates the development of standardized and individualized treatment plans and explores more effective treatments for patients with ALK ~ + DLBCL to benefit more patients. This study shared 1 case of ALK ~ + DLBCL high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (AHSCT) recurrence after treatment in Cancer Hospital of Tianjin Medical University in January 2012. The patients were treated with ALK kinase inhibitor crizotinib Crizotinib) cases of successful treatment.